Aβ propagation and strains: Implications for the phenotypic diversity in Alzheimer's disease
Open accessThe DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Abstract
The progressive nature of Alzheimer's disease (AD) is thought to occur, at least in part, by the self-replication and spreading of Aβ and Tau aggregates through a prion mechanism. Evidence now exists that structural variants of Aβ prions can propagate their distinct conformations through template-directed folding of naïve Aβ peptides. This notion implicates that the first self-propagating Aβ assembly to emerge in the brain dictates the conformation, anatomical spread and pace of subsequently formed deposits. It is hypothesized that a prion mechanism defines the molecular basis underlying the diverse clinicopathologic phenotypes observed across the spectrum of AD patients. Thus, distinct AD strains might require further sub-classification based on biochemical and structural characterization of aggregated Aβ. Here, we review the evidence for distinct, self-propagating Aβ strains, and discuss potential cellular mechanisms that might contribute to their manifestation. From this perspective, we also explore the implications of Aβ strains for current FDA-approved medical imaging probes and therapies for amyloid. Ultimately, the discovery of new molecular tools to differentiate Aβ strains and dissect the heterogeneity of AD may lead to the development of more informative diagnostics and strain-specific therapeutics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Neuroinflammation in Alzheimer's disease
Heneka, M. T., Carson, M. J., Khoury, J. E., Landreth, G. E., Brosseron, F., Feinstein, D. L., Jacobs, A. H., Wyss-Coray, T., Vitorica, J., Ransohoff, R. M., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)70016-5 · Cited by 6,226
The amyloid hypothesis of Alzheimer's disease at 25 years
Selkoe, D. J., & Hardy, J. (2016) · EMBO Molecular Medicine · doi:10.15252/emmm.201606210 · Cited by 6,164
TREM2 Variants in Alzheimer's Disease
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., Sassi, C., Kauwe, J. S. K., Younkin, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211851 · Cited by 3,020 · cited 1×
“Notably, the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) gene with loss-of-function mutations has emerged as one of the strongest single allele genetic risk factors for AD (Guerreiro et al. 2013, Jonsson et al. 2013, Jin et al. 2014, Ruiz et al. 2014, Korvatska et al. 2015).”
Variant of TREM2 Associated with the Risk of Alzheimer's Disease
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., Bjornsson, S., Huttenlocher, J., Levey, A. I., Lah, J. J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211103 · Cited by 2,558
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194 · cited 1×
“AD is characterized by a progressive cognitive decline in affected individuals and the postmortem observation of neuropathologic deposits composed of Amyloid-beta (Aβ) in extracellular plaques and intracellular hyperphosphorylated Tau in the form of neurofibrillary tangles (Braak et al. 2011)(Fig.”
A mutation in APP protects against Alzheimer’s disease and age-related cognitive decline
Jonsson, T., Atwal, J. K., Steinberg, S., Snaedal, J., Jonsson, P. V., Bjornsson, S., Stefansson, H., Sulem, P., Gudbjartsson, D., Maloney, J., et al. (2012) · Nature · doi:10.1038/nature11283 · Cited by 1,738
Self-Propagating, Molecular-Level Polymorphism in Alzheimer's ß-Amyloid Fibrils
Petkova, A. T., Leapman, R. D., Guo, Z., Yau, W.-M., Mattson, M. P., & Tycko, R. (2005) · Science · doi:10.1126/science.1105850 · Cited by 1,687
Self-propagation of pathogenic protein aggregates in neurodegenerative diseases
Jucker, M., & Walker, L. C. (2013) · Nature · doi:10.1038/nature12481 · Cited by 1,663
Curcumin has potent anti‐amyloidogenic effects for Alzheimer's β‐amyloid fibrils in vitro
Ono, K., Hasegawa, K., Naiki, H., & Yamada, M. (2004) · Journal of Neuroscience Research · doi:10.1002/jnr.20025 · Cited by 1,254 · cited 1×
“For example, curcumin has been shown to inhibit Aβ oligomer and fibril formation in vitro and reduce amyloid plaque deposition in vivo (Ono et al. 2004).”
Human ApoE isoforms differentially regulate brain amyloid-β peptide clearance
Castellano, J. M., Kim, J., Stewart, F. R., Jiang, H., DeMattos, R. B., Patterson, B. W., Fagan, A. M., Morris, J. C., Mawuenyega, K. G., Cruchaga, C., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002156 · Cited by 1,242
A three-dimensional human neural cell culture model of Alzheimer’s disease
Choi, S. H., Kim, Y. H., Hebisch, M., Sliwinski, C., Lee, S., D’Avanzo, C., Chen, H., Hooli, B., Asselin, C., Muffat, J., et al. (2014) · Nature · doi:10.1038/nature13800 · Cited by 1,195 · cited 1×
“Recent, three-dimensional human neuronal cultures show that genetic manipulation of cells to increase Aβ levels triggered its aggregation in vitro, leading to Tau phosphorylation (Choi et al. 2014).”
Structural conversion of neurotoxic amyloid-β1–42 oligomers to fibrils
Ahmed, M., Davis, J., Aucoin, D., Sato, T., Ahuja, S., Aimoto, S., Elliott, J. I., Van Nostrand, W. E., & Smith, S. O. (2010) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1799 · Cited by 1,111
Trafficking and Proteolytic Processing of APP
Haass, C., Kaether, C., Thinakaran, G., & Sisodia, S. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006270 · Cited by 1,075 · cited 7×
“APP is primarily cleaved by alpha-secretase resulting in non- amyloidogenic, soluble fragments of APP.”
InfluentialExogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host
Meyer-Luehmann, M., Coomaraswamy, J., Bolmont, T., Kaeser, S., Schaefer, C., Kilger, E., Neuenschwander, A., Abramowski, D., Frey, P., Jaton, A. L., et al. (2006) · Science · doi:10.1126/science.1131864 · Cited by 971 · cited 2×
“Under harsh denaturing conditions, Aβ losses its self-propagating activity, highlighting that distinct structural motifs are required for templating and propagation (Meyer-Luehmann et al. 2006).”
Jin, M., Shepardson, N., Yang, T., Chen, G., Walsh, D., & Selkoe, D. J. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017033108 · Cited by 876 · cited 1×
“Evidence for a cell-mediated relationship came from experiments exposing mouse neuronal cultures to patient-derived Aβ aggregates, which triggered Tau phosphorylation and cytoskeleton degeneration (Jin et al. 2011).”
Apolipoprotein E in Alzheimer’s disease and other neurological disorders
Verghese, P. B., Castellano, J. M., & Holtzman, D. M. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70325-2 · Cited by 857
Yuan, P., Condello, C., Keene, C. D., Wang, Y., Bird, T. D., Paul, S. M., Luo, W., Colonna, M., Baddeley, D., & Grutzendler, J. (2016) · Neuron · doi:10.1016/j.neuron.2016.05.003 · Cited by 817
Self-citationapoE isoform–specific disruption of amyloid β peptide clearance from mouse brain
Deane, R., Sagare, A., Hamm, K., Parisi, M., Lane, S., Finn, M. B., Holtzman, D. M., & Zlokovic, B. V. (2008) · Journal of Clinical Investigation · doi:10.1172/jci36663 · Cited by 771 · cited 1×
“…by astrocytes as well as cells composing the cerebrovasculature (Tai et al. 2016) and modulating its expression influences cerebral Aβ clearance and deposition in AD mouse models (DeMattos et al. 2004, Deane et al. 2008, Castellano et al. 2011, Youmans et al. 2012, Verghese et al. 2013).”
Microglia constitute a barrier that prevents neurotoxic protofibrillar Aβ42 hotspots around plaques
Condello, C., Yuan, P., Schain, A., & Grutzendler, J. (2015) · Nature Communications · doi:10.1038/ncomms7176 · Cited by 718
Self-citationJay, T. R., Miller, C. M., Cheng, P. J., Graham, L. C., Bemiller, S., Broihier, M. L., Xu, G., Margevicius, D., Karlo, J. C., Sousa, G. L., et al. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20142322 · Cited by 682 · cited 1×
“Trem2-knockout in AD mouse models abolishes the stereotypical clustering phenotype of activated microglia surrounding Aβ deposits, but the effects on plaque load are modest and may be stage-dependent (Ulrich et al. 2014, Jay et al. 2015, Wang et al. 2015).”
Heterogeneity of CNS myeloid cells and their roles in neurodegeneration
Prinz, M., Priller, J., Sisodia, S. S., & Ransohoff, R. M. (2011) · Nature Neuroscience · doi:10.1038/nn.2923 · Cited by 674
Iba, M., Guo, J. L., McBride, J. D., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2013) · The Journal of Neuroscience · doi:10.1523/jneurosci.2642-12.2013 · Cited by 664 · cited 1×
“…neurodegenerative diseases that the α-synuclein, Tau, TDP43 and SOD1 proteins can also adopt a self-propagating conformation upon misfolding (Luk et al. 2009, Guo et al. 2011, Volpicelli-Daley et al. 2011, Luk et al. 2012, Iba et al. 2013, Nonaka et al. 2013, Watts et al. 2013, Prusiner et al.”
Neuropathology of nondemented aging: presumptive evidence for preclinical Alzheimer disease
Price, J. L., McKeel, D. W., Buckles, V. D., Roe, C. M., Xiong, C., Grundman, M., Hansen, L. A., Petersen, R. C., Parisi, J. E., Dickson, D. W., et al. (2009) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2009.04.002 · Cited by 661 · cited 3×
“The assumption that the cerebral load of pathologic Aβ and Tau is sufficient to cause AD seems to be contradicted by a sizeable group of elderly individuals harboring AD pathology but do not exhibit symptoms (Price et al. 2009, SantaCruz et al. 2011).”
Heterogeneity of astrocytic form and function.
Oberheim, N. A., Goldman, S. A., & Nedergaard, M. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-452-0_3 · Cited by 638
Seeding of Normal Tau by Pathological Tau Conformers Drives Pathogenesis of Alzheimer-like Tangles
Guo, J. L., & Lee, V. M.-Y. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.209296 · Cited by 636
The Neuropathology of Chronic Traumatic Encephalopathy
McKee, A. C., Stein, T. D., Kiernan, P. T., & Alvarez, V. E. (2015) · Brain Pathology · doi:10.1111/bpa.12248 · Cited by 585 · cited 1×
“1993, Ishizawa et al. 2002, McKee et al. 2013, McKee et al. 2014, McKee et al. 2015, Kovacs et al. 2016).”
Vinters, H. V., & Gilbert, J. J. (1983) · Stroke · doi:10.1161/01.str.14.6.924 · Cited by 504
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
Johnson, K. A., Gregas, M., Becker, J. A., Kinnecom, C., Salat, D. H., Moran, E. K., Smith, E. E., Rosand, J., Rentz, D. M., Klunk, W. E., et al. (2007) · Annals of Neurology · doi:10.1002/ana.21164 · Cited by 495
ApoE and Clusterin Cooperatively Suppress Aβ Levels and Deposition
DeMattos, R. B., Cirrito, J. R., Parsadanian, M., May, P. C., O'Dell, M. A., Taylor, J. W., Harmony, J. A. K., Aronow, B. J., Bales, K. R., Paul, S. M., et al. (2004) · Neuron · doi:10.1016/s0896-6273(03)00850-x · Cited by 459 · cited 1×
“…by astrocytes as well as cells composing the cerebrovasculature (Tai et al. 2016) and modulating its expression influences cerebral Aβ clearance and deposition in AD mouse models (DeMattos et al. 2004, Deane et al. 2008, Castellano et al. 2011, Youmans et al. 2012, Verghese et al. 2013).”
Military-related traumatic brain injury and neurodegeneration
McKee, A. C., & Robinson, M. E. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.04.003 · Cited by 423
Dissecting phenotypic traits linked to human resilience to Alzheimer’s pathology
Perez-Nievas, B. G., Stein, T. D., Tai, H.-C., Dols-Icardo, O., Scotton, T. C., Barroeta-Espar, I., Fernandez-Carballo, L., de Munain, E. L., Perez, J., Marquie, M., et al. (2013) · Brain · doi:10.1093/brain/awt171 · Cited by 387 · cited 2×
“Some clues emerge from studies that look beyond plaque and tangle burden, and find that the brain levels of soluble oligomeric Aβ and glial inflammation can differentiate AD from NDHPC cases (Esparza et al. 2013, Perez-Nievas et al. 2013, Bilousova et al. 2016).”
Clinical, imaging, and pathological heterogeneity of the Alzheimer's disease syndrome
Lam, B., Masellis, M., Freedman, M., Stuss, D. T., & Black, S. E. (2013) · Alzheimer's Research & Therapy · doi:10.1186/alzrt155 · Cited by 386 · cited 1×
“The culmination of evidence for structurally distinct, self-propagating Aβ in AD might represent the molecular basis for the clinicopathologic heterogeneity seen across sporadic AD cases (Bird et al. 1989, Armstrong et al. 2000, Cupidi et al. 2010, Lam et al. 2013).”
Beecham, G. W., Hamilton, K., Naj, A. C., Martin, E. R., Huentelman, M., Myers, A. J., Corneveaux, J. J., Hardy, J., Vonsattel, J.-P., Younkin, S. G., et al. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004606 · Cited by 343
Apolipoprotein E4 effects in Alzheimer’s disease are mediated by synaptotoxic oligomeric amyloid-β
Koffie, R. M., Hashimoto, T., Tai, H.-C., Kay, K. R., Serrano-Pozo, A., Joyner, D., Hou, S., Kopeikina, K. J., Frosch, M. P., Lee, V. M., et al. (2012) · Brain · doi:10.1093/brain/aws127 · Cited by 327 · cited 1×
“Experimental studies have shown APOE4 to increase levels of oligomeric Aβ (Hashimoto et al. 2012, Tai et al. 2013), and enhance its localization to synaptic compartments (Koffie et al. 2012).”
Murray, M. E., Lowe, V. J., Graff-Radford, N. R., Liesinger, A. M., Cannon, A., Przybelski, S. A., Rawal, B., Parisi, J. E., Petersen, R. C., Kantarci, K., et al. (2015) · Brain · doi:10.1093/brain/awv050 · Cited by 324 · cited 2×
“Most moderate to late-stage AD patients show unambiguous amyloid positive PET scans (Klunk et al. 2004, Murray et al. 2015), but a minority of these cases appear negative despite biomarker and behavioral measures consistent with AD diagnosis (Rosen et al. 2010, Johnson et al. 2013, Landau et…”
Coding variants in TREM2 increase risk for Alzheimer's disease
Jin, S. C., Benitez, B. A., Karch, C. M., Cooper, B., Skorupa, T., Carrell, D., Norton, J. B., Hsu, S., Harari, O., Cai, Y., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu277 · Cited by 314 · cited 1×
“Notably, the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) gene with loss-of-function mutations has emerged as one of the strongest single allele genetic risk factors for AD (Guerreiro et al. 2013, Jonsson et al. 2013, Jin et al. 2014, Ruiz et al. 2014, Korvatska et al. 2015).”
Altered microglial response to Aβ plaques in APPPS1-21 mice heterozygous for TREM2
Ulrich, J. D., Finn, M. B., Wang, Y., Shen, A., Mahan, T. E., Jiang, H., Stewart, F. R., Piccio, L., Colonna, M., & Holtzman, D. M. (2014) · Molecular Neurodegeneration · doi:10.1186/1750-1326-9-20 · Cited by 302
Apolipoprotein E, Especially Apolipoprotein E4, Increases the Oligomerization of Amyloid β Peptide
Hashimoto, T., Serrano-Pozo, A., Hori, Y., Adams, K. W., Takeda, S., Banerji, A. O., Mitani, A., Joyner, D., Thyssen, D. H., Bacskai, B. J., et al. (2012) · The Journal of Neuroscience · doi:10.1523/jneurosci.1542-12.2012 · Cited by 294 · cited 1×
“Experimental studies have shown APOE4 to increase levels of oligomeric Aβ (Hashimoto et al. 2012, Tai et al. 2013), and enhance its localization to synaptic compartments (Koffie et al. 2012).”
Dickson, T. C., & Vickers, J. C. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00169-5 · Cited by 294
Immunotherapeutic Approaches for Alzheimer’s Disease
Wisniewski, T., & Goñi, F. (2015) · Neuron · doi:10.1016/j.neuron.2014.12.064 · Cited by 284 · cited 1×
“While most AD cases are sporadic with late-onset of disease, a minority of cases are heritable with most of the causative mutations altering Aβ production or and aggregation propensity leading to an early onset, familial form of AD (fAD) (Wolfe 2015).”
Johnson, K. A., Sperling, R. A., Gidicsin, C. M., Carmasin, J. S., Maye, J. E., Coleman, R. E., Reiman, E. M., Sabbagh, M. N., Sadowsky, C. H., Fleisher, A. S., et al. (2013) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2012.10.007 · Cited by 270
APOE4-specific Changes in Aβ Accumulation in a New Transgenic Mouse Model of Alzheimer Disease
Youmans, K. L., Tai, L. M., Nwabuisi-Heath, E., Jungbauer, L., Kanekiyo, T., Gan, M., Kim, J., Eimer, W. A., Estus, S., Rebeck, G. W., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.407957 · Cited by 268 · cited 2×
“…by astrocytes as well as cells composing the cerebrovasculature (Tai et al. 2016) and modulating its expression influences cerebral Aβ clearance and deposition in AD mouse models (DeMattos et al. 2004, Deane et al. 2008, Castellano et al. 2011, Youmans et al. 2012, Verghese et al. 2013).”
Characterizing the Appearance and Growth of Amyloid Plaques in APP/PS1 Mice
Yan, P., Bero, A. W., Cirrito, J. R., Xiao, Q., Hu, X., Wang, Y., Gonzales, E., Holtzman, D. M., & Lee, J.-M. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.2637-09.2009 · Cited by 264
The role of APOE in cerebrovascular dysfunction
Tai, L. M., Thomas, R., Marottoli, F. M., Koster, K. P., Kanekiyo, T., Morris, A. W. J., & Bu, G. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1547-z · Cited by 231
Some Speculations about Prions, Amyloid, and Alzheimer's Disease
Prusiner, S. B. (1984) · New England Journal of Medicine · doi:10.1056/nejm198403083101021 · Cited by 213
APOE2 enhances neuroprotection against Alzheimer’s disease through multiple molecular mechanisms
Conejero-Goldberg, C., Gomar, J. J., Bobes-Bascaran, T., Hyde, T. M., Kleinman, J. E., Herman, M. M., Chen, S., Davies, P., & Goldberg, T. E. (2014) · Molecular Psychiatry · doi:10.1038/mp.2013.194 · Cited by 199
Human APOE4 increases microglia reactivity at Aβ plaques in a mouse model of Aβ deposition
Rodriguez, G. A., Tai, L. M., LaDu, M. J., & Rebeck, G. W. (2014) · Journal of Neuroinflammation · doi:10.1186/1742-2094-11-111 · Cited by 193 · cited 1×
“Moreover, APOE4 expression increased microglial activation and altered the plaque morphological phenotype in transgenic mice (Youmans et al. 2012, Rodriguez et al. 2014).”
APOE ε2 is associated with milder clinical and pathological Alzheimer disease
Serrano‐Pozo, A., Qian, J., Monsell, S. E., Betensky, R. A., & Hyman, B. T. (2015) · Annals of Neurology · doi:10.1002/ana.24369 · Cited by 176 · cited 1×
“Conversely, AC CE PT ED M AN US CR IP T carriers of the APOE2 allele have milder AD symptoms despite relatively abundant pathology (Conejero-Goldberg et al. 2014, Serrano-Pozo et al. 2015, Shinohara et al. 2016), but much less is known about the mechanisms underlying this apparent protection.”
Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers
Schöll, M., Wall, A., Thordardottir, S., Ferreira, D., Bogdanovic, N., Långström, B., Almkvist, O., Graff, C., & Nordberg, A. (2012) · Neurology · doi:10.1212/wnl.0b013e31825fdf18 · Cited by 169 · cited 2×
“A subset of patients (bearing hypothetical Strain A) exhibit AD symptoms and fluid biomarkers antemortem and abundant neuropathology postmortem, but can test negative for amyloid PET signal (Rosen et al. 2010, Johnson et al. 2013, Landau et al. 2016, Tomiyama et al. 2008, Scholl et al. 2012).”
Tai, L. M., Bilousova, T., Jungbauer, L., Roeske, S. K., Youmans, K. L., Yu, C., Poon, W. W., Cornwell, L. B., Miller, C. A., Vinters, H. V., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.442103 · Cited by 165
Chalmers, K., Wilcock, G. K., & Love, S. (2003) · Neuropathology and Applied Neurobiology · doi:10.1046/j.1365-2990.2003.00457.x · Cited by 156
Korvatska, O., Leverenz, J. B., Jayadev, S., McMillan, P., Kurtz, I., Guo, X., Rumbaugh, M., Matsushita, M., Girirajan, S., Dorschner, M. O., et al. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.0979 · Cited by 137 · cited 1×
“Notably, the TREM2 (Triggering Receptor Expressed on Myeloid cells 2) gene with loss-of-function mutations has emerged as one of the strongest single allele genetic risk factors for AD (Guerreiro et al. 2013, Jonsson et al. 2013, Jin et al. 2014, Ruiz et al. 2014, Korvatska et al. 2015).”
Impact of sex and APOE4 on cerebral amyloid angiopathy in Alzheimer’s disease
Shinohara, M., Murray, M. E., Frank, R. D., Shinohara, M., DeTure, M., Yamazaki, Y., Tachibana, M., Atagi, Y., Davis, M. D., Liu, C.-C., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1580-y · Cited by 123
APOE2 eases cognitive decline during Aging: Clinical and preclinical evaluations
Shinohara, M., Kanekiyo, T., Yang, L., Linthicum, D., Shinohara, M., Fu, Y., Price, L., Frisch‐Daiello, J. L., Han, X., Fryer, J. D., et al. (2016) · Annals of Neurology · doi:10.1002/ana.24628 · Cited by 111
SantaCruz, K. S., Sonnen, J. A., Pezhouh, M. K., Desrosiers, M. F., Nelson, P. T., & Tyas, S. L. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31822e8ae9 · Cited by 79
In vivo imaging reveals sigmoidal growth kinetic of β-amyloid plaques
Burgold, S., Filser, S., Dorostkar, M. M., Schmidt, B., & Herms, J. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-30 · Cited by 59
Cited by
Protein misfolding, aggregation, and conformational strains in neurodegenerative diseases
Soto, C., & Pritzkow, S. (2018) · Nature Neuroscience · doi:10.1038/s41593-018-0235-9 · Cited by 1,180
New Insights Into the Pathogenesis of Alzheimer's Disease
Fan, L., Mao, C., Hu, X., Zhang, S., Yang, Z., Hu, Z., Sun, H., Fan, Y., Dong, Y., Yang, J., et al. (2020) · Frontiers in Neurology · doi:10.3389/fneur.2019.01312 · Cited by 344
Oral Microbiota and Alzheimer’s Disease: Do All Roads Lead to Rome?
Sureda, A., Daglia, M., Argüelles Castilla, S., Sanadgol, N., Fazel Nabavi, S., Khan, H., Belwal, T., Jeandet, P., Marchese, A., Pistollato, F., et al. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2019.104582 · Cited by 143
Cellular Receptors of Amyloid β Oligomers (AβOs) in Alzheimer’s Disease
Mroczko, B., Groblewska, M., Litman-Zawadzka, A., Kornhuber, J., & Lewczuk, P. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19071884 · Cited by 97
“Implications for the phenotypic diversity of Aβ in AD include clinical and neuropathological heterogeneity of AD, various distribution and significant differences in the expression of Aβ species in brain tissue, as well as different concentrations of Aβ peptides in CSF of AD patients [69].”
BackgroundMaxwell, A. M., Yuan, P., Rivera, B. M., Schaaf, W., Mladinov, M., Prasher, V. P., Robinson, A. C., DeGrado, W. F., & Condello, C. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01298-0 · Cited by 23
Self-citation
Metadata
- Authors
- Condello, C., & Stöehr, J.
- Venue
- Neurobiology of Disease
- Publisher
- Elsevier BV
- Published
- 2018-01
- Volume
- 109
- Issue
- Pt B
- Pages
- 191-200
- ISSN
- 0969-9961 (ISSN-L)
- OpenAlex
- W2600215207
- Cited by
- 86
- References
- 57
- FWCI
- 7.04
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.